Astrazeneca plc ADR (NASDAQ: AZN) has a higher price-to-earnings ratio of 33.73x compared to its average ratio. compared to its average ratio and a 36-month beta value of 0.51. Analysts have mixed views on the stock, with 24 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”

The average price point forecasted by analysts for Astrazeneca plc ADR (AZN) is $82.69, which is $18.9 above the current market price. The public float for AZN is 3.10B, and currently, short sellers hold a 0.29% ratio of that float. The average trading volume of AZN on November 21, 2023 was 5.23M shares.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


AZN) stock’s latest price update

The stock price of Astrazeneca plc ADR (NASDAQ: AZN) has plunged by -0.53 when compared to previous closing price of 64.13, but the company has seen a 0.14% gain in its stock price over the last five trading sessions. InvestorPlace reported 2023-11-20 that This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.

AZN’s Market Performance

Astrazeneca plc ADR (AZN) has seen a 0.14% rise in stock performance for the week, with a -0.06% decline in the past month and a -7.24% plunge in the past quarter. The volatility ratio for the week is 1.00%, and the volatility levels for the past 30 days are at 1.46% for AZN. The simple moving average for the last 20 days is 0.25% for AZN stock, with a simple moving average of -7.59% for the last 200 days.

Analysts’ Opinion of AZN

Many brokerage firms have already submitted their reports for AZN stocks, with Jefferies repeating the rating for AZN by listing it as a “Buy.” The predicted price for AZN in the upcoming period, according to Jefferies is $80 based on the research report published on September 25, 2023 of the current year 2023.

AZN Trading at -3.01% from the 50-Day Moving Average

After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.68% of loss for the given period.

Volatility was left at 1.46%, however, over the last 30 days, the volatility rate increased by 1.00%, as shares surge +1.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.22% lower at present.

During the last 5 trading sessions, AZN rose by +0.14%, which changed the moving average for the period of 200-days by +0.55% in comparison to the 20-day moving average, which settled at $63.67. In addition, Astrazeneca plc ADR saw -5.91% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for AZN

Current profitability levels for the company are sitting at:

The net margin for Astrazeneca plc ADR stands at +7.41. The total capital return value is set at 7.69, while invested capital returns managed to touch 5.30. Equity return is now at value 16.30, with 6.20 for asset returns.

Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 78.93 points at debt to equity in total, while total debt to capital is 44.11. Total debt to assets is 30.30, with long-term debt to equity ratio resting at 63.96. Finally, the long-term debt to capital ratio is 35.75.

When we switch over and look at the enterprise to sales, we see a ratio of 4.85, with the company’s debt to enterprise value settled at 0.13. The receivables turnover for the company is 4.88 and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.


To put it simply, Astrazeneca plc ADR (AZN) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.